Bayesian Capital Management’s Invesco IVZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$311K Buy
+11,800
New +$313K 0.2% 147
2024
Q1
Sell
-73,200
Closed -$1.31M 943
2023
Q4
$1.31M Buy
73,200
+48,500
+196% +$700K 0.14% 183
2023
Q3
$359K Sell
24,700
-9,800
-28% -$158K 0.04% 428
2023
Q2
$580K Buy
+34,500
New +$555K 0.06% 375
2022
Q4
Sell
-24,600
Closed -$337K 899
2022
Q3
$337K Buy
24,600
+11,000
+81% +$186K 0.07% 377
2022
Q2
$219K Buy
+13,600
New +$257K 0.04% 591
2021
Q4
Sell
-9,300
Closed -$224K 451
2021
Q3
$224K Sell
9,300
-11,809
-56% -$295K 0.06% 328
2021
Q2
$564K Buy
+21,109
New +$575K 0.15% 175
2019
Q4
Sell
-12,000
Closed -$203K 673
2019
Q3
$203K Buy
+12,000
New +$212K 0.04% 446
2019
Q2
Sell
-21,400
Closed -$413K 593
2019
Q1
$413K Buy
+21,400
New +$400K 0.08% 329

Other funds holding IVZ

Bayesian Capital Management's IVZ Position: Q2 2026 in Review

Bayesian Capital Management opened a new position in Invesco (IVZ) in Q2 2026: 11,800 shares worth $311K. The stake represents 0.2% of the portfolio and ranks #147 among its holdings. This is a return to the name: Bayesian Capital Management previously reported a position in IVZ as recently as Q4 2023.

Bayesian Capital Management first reported a position in IVZ in Q1 2019 and has held it in 10 quarters since. The position peaked at $1.31M in Q4 2023. 668 funds tracked by Wall St. Rank hold IVZ as of Q2 2026.

  • Bayesian Capital Management held 11,800 shares of Invesco worth $311K as of Q2 2026.
  • Invesco was a new Bayesian Capital Management position in Q2 2026.
  • Invesco made up 0.2% of Bayesian Capital Management's portfolio in Q2 2026, its #147 holding.
  • Bayesian Capital Management first reported a position in Invesco in Q1 2019 and has held it in 10 quarters since.
  • Bayesian Capital Management's Invesco position peaked at $1.31M in Q4 2023.
  • 668 funds tracked by Wall St. Rank held Invesco as of Q2 2026.

Based on Bayesian Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.